Humacyte (HUMA) vs Atrium Therapeutics (RNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Atrium Therapeutics is the larger company by market cap ($137.7 million vs $125.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HUMA | RNA |
|---|---|---|
| Share price | $0.4501 | $8.05 |
| Market cap | $125.04M | $137.70M |
| 1-day change | -4.70% | +1.51% |
| YTD return | -50.85% | — |
| 1-year return | -71.29% | — |
| 5-year return | -95.38% | — |
| EPS (TTM) | $-0.51 | $-5.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.90 | $16.77 |
| 52-week low | $0.45 | $7.63 |
| Distance from 52-week high | -76.25% | -52.00% |
| Analyst consensus | buy | none |
| Avg. price target upside | +262.14% | +210.56% |
| Average volume | 6.30M | 253.00K |
| Shares outstanding | 277.80M | 17.11M |
| Employees | 184 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Humacyte
HUMA stock →Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 184 employees
About Atrium Therapeutics
RNA stock →Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
Health Care · Biotechnology: Pharmaceutical Preparations
HUMA vs RNA FAQ
Which is bigger, Humacyte or Atrium Therapeutics?
Atrium Therapeutics (RNA) is larger, with a market capitalization of $137.70M compared with $125.04M for Humacyte (HUMA).
Are Humacyte and Atrium Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Humacyte and Biotechnology: Pharmaceutical Preparations for Atrium Therapeutics.